The SH2-U-box targets both native and T315I-mutant BCR-ABL for ubiquitination and degradation and thus may serve as a tool for treating both imatinib-sensitive and imatinib-resistant CML (Ru et al., 2016). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.